Abstract: Fabric treatment compositions that include benefit agent capsules and biphenyl brightener. Methods of using the same. Wash water that includes such compositions.

Abstract: A method for producing polysulfone micro-particles for 3D printing disclosed. For example, the method includes creating a mixture of polysulfone by dissolving polysulfone in an organic solvent, creating an aqueous solution of a polymeric stabilizer or a surfactant, adding the mixture of polysulfone to the aqueous solution to create a polysulfone solution, and processing the polysulfone solution to obtain polysulfone micro-particles having a desired particle size, a desired particle size distribution, and a desired shape.

Abstract: Described herein are sustained release formulations of polymer-coated local anesthetic agents, and methods for using the same to relieve or manage pain, including postsurgical pain.

Abstract: Liquid fabric treatment compositions that include benefit agent capsules, brightener, and a quaternary ammonium ester softening active. Methods of making and using such compositions.

Abstract: Fabric treatment compositions that include benefit agent capsules and diaminostilbene brightener. Methods of using the same. Wash water containing such compositions.

Abstract: Methods and devices for producing a population of liposomes are provided. Aspects of the methods include applying a centrifugal force to a suspension of liposomes in a manner sufficient to pass the liposomes through a porous membrane to produce a population of liposomes. Aspects of the invention further include devices, systems and kits useful for performing the methods.

Abstract: Methods, compositions, and kits for stabilizing both human and microbial deoxyribonucleic acid (DNA) present in complex biological samples, such as feces, are disclosed. In particular, aqueous compositions for stabilizing DNA contained in biological samples at ambient temperature are disclosed, together with associated methods and kits using same. In one aspect, the compositions comprise a chelating agent present at a concentration of at least about 150 mM, and the composition has a pH of at least about 9.5.

Abstract: Giant multi-lamellar vesicles (GMVs) comprising lecithin are provided which are at least about 3 ?m in size. Methods for preparing the GMVs, and for preparing large unilamellar vesicles (LUVs) from the GMVs, are provided, as well as methods for encapsulating cargo within the GMVs and LUVs. The present vesicles are useful for the oral delivery of encapsulated cargo.

Abstract: A heat-storage composition includes a resin and a heat storage material. The composition has a viscosity of 100 to 1,000 dPa·s, as measured with a cylinder-type rotational viscometer. The composition also has a storage elastic modulus (G?) of 3 Pa or more at an angular frequency of 1 rad/s, as measured by a dynamic viscoelasticity measurement method at a temperature of 25° C. and at a strain of 0.1%.

Abstract: The present disclosure relates to processes for preparing microparticles using an emulsion process where both a solvent and a salt are used in the continuous phase of the emulsion. The present disclosure also relates to microparticles having an angle of repose of ?35, as measured using a Hele-Shaw cell.

Abstract: Processes and apparatuses for producing biologically-active, protein-rich microparticles under ambient conditions are disclosed. A protein solution is atomized and collected in a dehydration solvent that is being mixed. The resulting protein microparticles retain high specific activity without the need for large amounts of stabilizing excipients.

Abstract: The present invention provides a hemostatic porous composite sponge comprising: i) a matrix of a biomaterial; and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or said matrix is impregnated with said polymeric material, or both.

Abstract: Methods, compositions, and kits for stabilizing both human and microbial deoxyribonucleic acid (DNA) present in complex biological samples, such as feces, are disclosed. In particular, aqueous compositions for stabilizing DNA contained in biological samples at ambient temperature are disclosed, together with associated methods and kits using same. In one aspect, the compositions comprise a chelating agent present at a concentration of at least about 150 mM, and the composition has a pH of at least about 9.5.

Abstract: Provided is a solid anhydrous composition that comprises particles comprising a core containing at least one beneficial agent and an envelope surrounding the core. The envelope comprises at least one hydrophobically modified polysaccharide and at least one water-soluble carbohydrate and/or water-soluble polyol. The particles simultaneously have a poured powder density ranging from 300.0 g/l to 600.0 g/l and an absolute density of greater than 1.0. The envelope also comprises at least one structuring agent. Also provided is a cosmetic process for caring for and/or for the hygiene of and/or for conditioning and/or for fragrancing and/or for making up keratin material. The process comprises applying to the keratin material the above composition. Also provided is a cosmetic process for treating body odor and optionally human perspiration, which comprises applying to a keratin material a composition defined above comprising at least one deodorant and/or antiperspirant in free form and/or in encapsulated form.

Abstract: The present invention provides a pharmaceutical composition containing Guaifenesin. The invention pharmaceutical composition comprises a core containing Guaifenesin and a coating layer encapsulating the core containing Guaifenesin, and the coating layer comprises a plasticizer and a polymer, wherein the polymer is applied in the range of approximately 5 wt. % to 35 wt. % based on the total weight of the pharmaceutical composition. A method for controlled releasing an expectorant agent is also provided in the present invention.

Abstract: The present invention provides novel liposomal formulations of polymyxin B and pharmaceutical compositions thereof useful for the treatment of bacterial infections. The liposomal formulation comprises a lipid component formed as vesicles each having a minimum size of at least 500 nm and polymyxin B encapsulated in the vesicles. The present invention also provides a drug delivery system that comprises a plurality of liposomes encapsulating a polymyxin B therein, where the liposomes have a minimum vesicular size of at least 500 nm. The liposomes comprising the drug delivery system are useful to increase efficacy of a treatment for a bacterial infection by increasing bioavailability and distribution of the polymyxin B within the subject.

Abstract: A hybrid diafiltration system includes an intermediate tank, a feed pump and a single-pass concentration (SPC) module, feed and product flow diverting valves to affect a multi-step concentration, wash and final-concentration process with fewer recirculation passes than conventional systems.

Abstract: Micro-capsules for the slow release of drugs, consisting of a lactic-co-glycolic copolymer to which a plasticizer has been incorporated and which contain a drug of pharmaceutical interested within them.

Abstract: Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients.

Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.

Abstract: The present invention relates to dried reconstituted vesicle (DRV) compositions and water based formulations thereof, which contain one or more therapeutic agents (e.g. hydrophilic protein). More particularly, it relates to DRVs comprising at least one lipid and a fusion promoting agent which after reconstitution form large multilamellar liposomes encapsulating an active agent in an aqueous phase.

Abstract: Prior art processes for producing protein-based capsules (for example, capsules for use in electrophoretic media) tend to be wasteful because they produce many capsules outside the desired size range, which is typically about 20 to 50 ?m. Capsule size distribution and yields can be improved by either (a) emulsifying a water-immiscible phase in a preformed coacervate of the protein; or (b) using a limited coalescence process with colloidal alumina as the surface-active particulate material.

Abstract: A method for controlling a particle diameter and a particle diameter distribution of emulsion particles during manufacturing of an emulsion dispersion is provided. The method includes causing two or more types of liquids substantially immiscible with each other to continuously and sequentially pass through net bodies. The net bodies are disposed in a cylindrical flow passage at intervals of 5 to 200 mm, and the number of the net bodies is more than 50 and 200 or less. Each of the net bodies is equivalent to a gauze having a mesh number of 35 mesh to 4000 mesh in accordance with an ASTM standard and has a surface that intersects the direction of the flow passage. An emulsification apparatus used for the method includes a feed pump for feeding two or more types of liquids substantially immiscible with each other; and a cylindrical flow passage to which the two or more types of liquids fed by the feed pump are delivered.

Abstract: The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.

Abstract: The present invention relates to a method for producing mesoporous silica particles including a silica-containing outer shell portion with a mesoporous structure. The method includes the steps of: (I) pressurizing a mixed solution containing a hydrophobic organic compound, a surfactant, and an aqueous solvent by a high-pressure emulsification method so as to form an emulsion that includes emulsion droplets containing the hydrophobic organic compound; (II) adding a silica source to the emulsion so as to form a silica-containing outer shell portion with a mesoporous structure on a surface of the emulsion droplets, and precipitating composite silica particles including the outer shell portion and the emulsion droplets on an inner side relative to the outer shell portion; and (III) removing the emulsion droplets from the composite silica particles.

Abstract: The invention relates to a method for producing microparticles or nanoparticles of water-soluble and water-insoluble substances by controlled precipitation, co-precipitation and self-organization processes in microjet reactors, a solvent, which contains at least one target molecule, and a nonsolvent being mixed as jets that collide with each other in a microjet reactor at defined pressures and flow rates and thereby effect very rapid precipitation, co-precipitation or a chemical reaction, during the course of which microparticles or nanoparticles are formed.

Abstract: The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.

Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Abstract: The present systems and methods utilize a polyamic acid solution as a precursor to form a polyimide bead having desired properties. The polyamic acid solution may be formed into a polyamic acid droplet. The polyamic acid droplet is then processed to form a polyamic acid bead, such as by extraction of solvent to concentrate the polyamic acid or by partial chemical imidization of the polyamic acid. The polyamic acid bead is then better able to retain its shape during subsequent processing steps, such as drying and pressurizing, before final thermal imidization.

Abstract: The present invention provides for methods of preparing silk nanoparticles and microparticles, methods of encapsulating an active agent into the silk nano- and microparticles and compositions comprising these silk particles.

Abstract: Pharmaceutical drug particles of small particle size are produced by combining a solvent-non-solvent precipitate with an in-situ spray drying process. A pharmaceutical drug is dispersed in a water-miscible solvent, in particular ethanol, and heated in an infeed line under pressure to above the boiling point of the solvent until the drug dissolves. This solution collides as a fine liquid jet with a fine water jet in a gas-permeated microreactor, and the fine mist so arising vaporises rapidly. The organic solvent vaporizes first, then the water. The water may contain surface modifiers.

Abstract: Processes for the preparation of bio-based fiber gums and products produced by these processes and some of their uses.

Abstract: The invention provides a method for encapsulating a liquid, which method comprises the steps of providing a suspension of droplets of the liquid to be encapsulated; stabilizing the suspension of droplets with a surfactant; adding a layered inorganic material to the stabilized suspension; and subjecting the suspension to a treatment which establishes that a shell of a hybrid material is formed around the droplets, which hybrid material comprises at least part of the inorganic material and at least part of the surfactant. The invention further provides encapsulated liquid droplets obtainable by said method.

Abstract: The present invention provides a method for forming a multicompartmentalized vesicular structure comprising an outer block copolymer vesicle and at least one inner block copolymer vesicle, wherein the at least one inner block copolymer vesicle is encapsulated inside the outer block copolymer vesicle. The method comprises forming the at least one inner block copolymer vesicle by any method and adding block copolymers dissolved in a suitable solvent to a dispersion of the at least one inner block copolymer vesicle in an aqueous buffer under conditions that allow the block copolymers to form the outer block copolymer vesicle and encapsulate the at least one inner block copolymer vesicle. A multicompartmentalized vesicular structure and its uses are also provided.

Abstract: The present invention relates to an amphiphilic cyclic phosphazene trimer which is biocompatible and a method for preparing the same. The present invention also relates to pharmaceutical formulations of hydrophobic drugs that are micelle-encapsulated by the amphiphilic cyclic phosphazene trimer and a method for preparing the same.

Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.

Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.

Abstract: Particles having a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups.